Selected Publications
EVI1 drives leukemogenesis through aberrant ERG activation
Schmoellerl J, Barbosa IAM, Minnich M, Andersch F, Smeenk L, Havermans M, Eder T, Neumann T, Jude J, Fellner M, Ebert A, Steininger M, Delwel R, Grebien F, Zuber J
Blood; September 2022, available at https://doi.org/10.1182/blood.2022016592
Comprehensive assessment of differential ChIP-seq tools guides optimal algorithm selection
Eder T, Grebien F
Genome Biology; May 2022, available at https://doi.org/10.1186/s13059-022-02686-y
2023
SBNO2 is a critical mediator of STAT3-driven hematological malignancies. Brandstoetter T, Schmoellerl J, Grausenburger R, Kollmann S, Doma E, Huuhtanen J, Klampfl T, Eder T, Grebien F, Hoermann G, Zuber J, Mustjoki S, Maurer B, Sexl V.
Blood. January 2023. Online ahead of print. available at https://10.1182/blood.2022018494
2022
Arrayed CRISPR/Cas9 Screening for the Functional Validation of Cancer Genetic Dependencies. Proietti L, Manhart G, Heyes E, Troester S, Grebien F.
Bio Protoc; December 2022. available at https://doi.org/10.21769/BioProtoc.4577
Decoding molecular programs in melanoma brain metastases. Radke J, Schumann E, Onken J, Koll R, Acker G, Bodnar B, Senger C, Tierling S, Möbs M, Vajkoczy P, Vidal A, Högler S, Kodajova P, Westphal D, Meier F, Heppner F, Kreuzer-Redmer S, Grebien F, Jürchott K, Redmer T.
Nat Commun. November 2022. available at https://doi.org/10.1038/s41467-022-34899-x
Antiviral immune response reveals host-specific virus infections in natural ant populations.
Viljakainen L, Fuerst M, Grasse A, Jurvansuu J, Oh J, Tolonen L, Eder T, Rattei T, Cremer S.
bioRxiv; October 2022. available at https://doi.org/10.1101/2022.10.17.512467
EVI1 drives leukemogenesis through aberrant ERG activation.
Schmoellerl J, Barbosa IAM, Minnich M, Andersch F, Smeenk L, Havermans M, Eder T, Neumann T, Jude J, Fellner M, Ebert A, Steininger M, Delwel R, Grebien F, Zuber J.
Blood; September 2022. available at https://doi.org/10.1182/blood.2022016592
Identification of CD4+ T cells with T follicular helper cell characteristics in the pig.
Hoog A, Villanueva-Hernández S, Adib Razavi M, van Dongen K, Eder T, Piney L, Chapat L, de Luca K, Grebien F, Mair KH, Gerner W.
Dev. Comp Immunology; September 2022, available at https://doi.org/10.1016/j.dci.2022.104462
A Journey Into the Unknown: PhD Students in a European Training Network on Age-related Changes in Hematopoiesis Conduct Their Project During a Global Pandemic
Pitsillidou C, Alonso-Rubido S , Ávila-Ávila A, Romero-Mulero MC, Labedz A, Oikonomou A, Proietti L, Psychoyiou ME, Tellez-Quijorna C, Hillary M, Fasouli ES, Fernández-Rodríguez G, Giner-Laguarda N, Skinder N, Taroni C, Strouboulis J, Katsantoni E, Ronchi AE
Hemasphere; August 2022, available at doi: 10.1097/HS9.0000000000000763.
Increasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology.
Perkmann T, Koller T, Perkmann-Nagele N, Ozsvar-Kozma M, Eyre D, Matthews P, Bown A, Stoesser N, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, Aletaha D, Sieghart D, Quehenberger P, Marculescu R, Mucher P, Radakovics A, Klausberger M, Duerkop M, Holzer B, Hartmann B, Strassl R, Leitner G, Grebien F, Gerner W, Grabherr R, Wagner OF, Binder CJ, Haslacher H.
J Clin Pathol.; August 2022, available at https://doi.org/10.1136/jcp-2022-208171
Comprehensive assessment of differential ChIP-seq tools guides optimal algorithm selection.
Eder, T, Grebien, F.
Genome Biol.; May 2022, available at https://doi.org/10.1186/s13059-022-02686-y
Designed SARS-CoV-2 receptor binding domain variants form stable monomers.
Klausberger M, Kienzl NF, Stadlmayr G, Grünwald-Gruber C, Laurent E, Stadlbauer K, Stracke F, Vierlinger K, Hofner M, Manhart G, Gerner W, Grebien F, Weinhäusel A, Mach L, Wozniak-Knopp G.
Biotechnol J.; January 2022, available at https://onlinelibrary.wiley.com/doi/10.1002/biot.202100422. Online ahead of print.
2021
Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness.
Grandits AM, Nguyen CH, Schlerka A, Hackl H, Sill H, Etzler J, Heyes E, Stoiber D, Grebien F, Heller G, Wieser R.
Leukemia; October 2021, available at https://www.nature.com/articles/s41375-021-01224-2.
Impact of Specific N-Glycan Modifications on the Use of Plant-Produced SARS-CoV-2 Antigens in Serological Assays.
Schwestka J, König-Beihammer J, Shin YJ, Vavra U, Kienzl NF, Grünwald-Gruber C, Maresch D, Klausberger M, Laurent E, Stadler M, Manhart G, Huber J, Hofner M, Vierlinger K, Weinhäusel A, Swoboda I, Binder CJ, Gerner W, Grebien F, Altmann F, Mach L, Stöger E, Strasser R.
Front Plant Sci.; September 2021, available at https://www.frontiersin.org/articles/10.3389/fpls.2021.747500/full.
Discovery of a Non-Nucleoside SETD2 Methyltransferase Inhibitor against Acute Myeloid Leukemia
Bajusz D†, Bognár Z†, Ebner J†, Grebien F, Keserű GM
Int. J. Mol. Sci.; September 2021, available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471172/.
Exploring protein hotspots by optimized fragment pharmacophores
Bajusz D, Wade WS, Satała G, Bojarski AJ, Ilaš J, Ebner J, Grebien F, Papp H, Jakab F, Douangamath A, Fearon D, von Delft F, Schuller M, Ahel I, Wakefield A, Vajda S, Gerencsér J, Pallai P & Keserű GM
Nature Communications; May 2021, available at https://www.nature.com/articles/s41467-021-23443-y
Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter
van der Kouwe E, Heller G, Czibere A, Pulikkan JA, Agreiter C, Castilla LH, Delwel R, Di Ruscio A, Ebralidze AK, Forte M, Grebien F, Heyes E, Kazianka L, Klinger J, Kornauth C, Le T, Lind K, Inês Amorim Monteiro Barbosa, Pemovska T, Pichler AS, Schmolke AS, Schweicker CM, Sill H, Sperr WR, Spittler A, Surapally S, Trinh BQ, Valent P, Vanura K, Welner RS, Zuber J, Tenen DG, Staber PB
Blood; May 2021, available at doi: 10.1182/blood.2020008971. Online ahead of print.
Regulation of the Mitochondrion-Fatty Acid Axis for the Metabolic Reprogramming of Chlamydia trachomatis during Treatment with β-Lactam Antimicrobials
Shima K , Kaufhold I, Eder T , Käding N, Schmidt N, Ogunsulire IM, Deenen R, Köhrer K, Friedrich D, Isay SE, Grebien F, Klinger M, Richer BC, Günther UL, Deepe Jr GS , Rattei T, Rupp J.
mBio; March 2021, available at https://mbio.asm.org/content/12/2/e00023-21.long
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Winter G, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T,Constantinescu SN, Kralovics R, Sexl V, Skoda R, Superti-Furga G,4 and Jäger U.
Hemasphere, March 2021, available at https://pubmed.ncbi.nlm.nih.gov/33623882/
Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML
Heyes E, Schmidt L, Manhart G, Eder T, Proietti L, Grebien F.
Leukemia; February 2021, available at https://www.nature.com/articles/s41375-021-01169-6
Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression
Terlecki-Zaniewicz S, Humer T, Eder T, Schmoellerl J, Heyes E, Manhart G, Kuchynka N, Parapatics K, Liberante FG, Müller AC, Tomazou EM, Grebien F.
Nature Structural & Molecular Biology; January 2021, available at https://nature.com/articles/s41594-020-00550-w
2020
Mol Metab. 2020 Oct;40:101026. doi: 10.1016/j.molmet.2020.101026. available at https://pubmed.ncbi.nlm.nih.gov/32473405/
Cancers (Basel). 2020 Sep 26;12(10). doi: 10.3390/cancers12102766. available at https://pubmed.ncbi.nlm.nih.gov/32993115/
CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia
Schmoellerl J, Barbosa I, Eder T, Brandstoetter T, Schmidt L, Maurer B, Troester S, Pham HTT, Sagarajit M, Ebner J, Manhart G, Aslan E, Terlecki-Zaniewicz S, Van der Veen C, Hoermann G, Duployez N, Petit A, Lapillonne H, Puissant A, Itzykson RA, Moriggl RH, Heuser M, Meisel R, Valent P, Sexl V, Zuber J, Grebien F.
Blood; April 2020, pii: blood.2019003267, available at https://www.ncbi.nlm.nih.gov/pubmed/32344427
Gain‐of‐Function Effects of N‐Terminal CEBPA Mutations in Acute Myeloid Leukemia
Schmidt L, Heyes E, Grebien F.
BioEssays; January 2020, 1900178, available at https://pubmed.ncbi.nlm.nih.gov/31867767/
HBO1 is required for the maintenance of leukaemia stem cells
MacPherson L, Anokye J, Yeung MM, Lam EYN, Chan Y-C, Weng C-F, Yeh P, Knezevic K, Butler MS, Hoegl A, Chan K-L, Burr ML, Gearing LJ, Willson T, Liu J, Choi J, Yang Y, Bilardi RA, Falk H, Nguyen N, … , Grebien F, Dawson SJ, Street IP, Monahan BJ, Burns CJ, Choudhary , Blewitt ME, Voss AK, Thomas T & Dawson MA.
Nature; January 2020, 577: 266–270, available at https://pubmed.ncbi.nlm.nih.gov/31827282/
Haematologica. 2020;105(2):435-447. doi: 10.3324/haematol.2019.216986. available at https://pubmed.ncbi.nlm.nih.gov/31123029/
2019
All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia
Nguyen CH, Bauer K, Hackl H, Schlerka A, Koller E, Hladik A, Stoiber D, Zuber J, Staber PB, Hoelbl-Kovacic A, Purton LE, Grebien F, Wieser R.
Cell Death and Disease; December 2019, 10(12):944, available at https://pubmed.ncbi.nlm.nih.gov/31822659/
A kinase-independent role for CDK8 in BCR-ABL1+ leukemia
Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, Edlinger L, Knab VM, Uras IZ, Grundschober E, Bauer K, Roth M, Skucha A, Liu Y, Hatcher JM, Liang Y, Kwiatkowski NP, Fux D, Hoelbl-Kovacic A, Kubicek S, Melo JV, Valent P, Weichhart T, Grebien F, Zuber J, Gray NS, Sexl V.
Nature Communications; October 2019, 10(1):4741. available at https://pubmed.ncbi.nlm.nih.gov/31628323/
CEBPA-Mutated Leukemia Is Sensitive to Genetic and Pharmacological Targeting of the MLL1 Complex
Schmidt L, Heyes E, Scheiblecker L, Eder T, Volpe G, Frampton J, Nerlov C, Valent P, Grembecka J, Grebien F.
Leukemia; July 2019, 33(7): 1608–19, available at http://www.ncbi.nlm.nih.gov/pubmed/30679799
STAT3β Is a Tumor Suppressor in Acute Myeloid Leukemia
Aigner P, Mizutani T, Horvath J, Eder T, Heber S, Lind K, Just V, Moll HP, Yeroslaviz A, Fischer MJM, Kenner L, Győrffy B, Sill H, Grebien F, Moriggl R, Casanova E, Stoiber D.
Blood Advances; July 2019, 3(13): 1989–2002, available at https://www.ncbi.nlm.nih.gov/pubmed/31270081
High Activation of STAT5A Drives Peripheral T-Cell Lymphoma and Leukemia
Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer A-I, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R
Haematologica; May 2019, available at http://www.ncbi.nlm.nih.gov/pubmed/31123029
The Phosphatase UBASH3B/Sts-1 Is a Negative Regulator of Bcr-Abl Kinase Activity and Leukemogenesis
Mian AA, Baumann I, Liebermann M, Grebien F, Superti-Furga G, Ruthardt M, Ottmann OG, Hantschel O
Leukemia; April 2019, available at http://www.ncbi.nlm.nih.gov/pubmed/30962580
Dependence on Myb Expression Is Attenuated in Myeloid Leukaemia with N-Terminal CEBPA Mutations
Volpe G, Cauchy P, Walton DS, Ward C, Blakemore D, Bayley R, Clarke ML, Schmidt L, Nerlov C, Garcia P, Dumon S, Grebien F, Frampton J
Life Science Alliance; April 2019, 2(2): e201800207, available at https://www.ncbi.nlm.nih.gov/pubmed/30877232
Dependency on the TYK2/STAT1/MCL1 Axis in Anaplastic Large Cell Lymphoma
Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O
Leukemia; March 2019, 33(3): 696–709, available at http://www.ncbi.nlm.nih.gov/pubmed/30131584
Altered Splicing and Cytoplasmic Levels of TRNA Synthetases in SF3B1-Mutant Myelodysplastic Syndromes as a Therapeutic Vulnerability
Liberante FG, Lappin K, Barros EM, Vohhodina J, Grebien F, Savage KI, Mills KI
Scientific reports; February 2019, 9(1): 2678, available at http://www.ncbi.nlm.nih.gov/pubmed/30804405
Roles of Setd2 in Leukemia—Transcription, Dna-Damage, and Beyond
Skucha A, Ebner J, Grebien F
International Journal of Molecular Sciences; February 2019, 20(5), available at http://www.ncbi.nlm.nih.gov/pubmed/30818762
2018
SETD2 in MLL-Rearranged Leukemia – a Complex Case
Skucha A, Ebner J, Grebien F
Molecular & cellular oncology; August 2018, 5(4): e1503492, available at http://www.ncbi.nlm.nih.gov/pubmed/30250934
Oxytocin-like Signaling in Ants Influences Metabolic Gene Expression and Locomotor Activity
Liutkevičiutė Z, Gil-Mansilla E, Eder T, Casillas-Pérez B, Di Giglio MG, Muratspahić E, Grebien F, Rattei T, Muttenthaler M, Cremer S, Gruber CW
FASEB Journal; June 2018, 32(12): 6808–21, available at http://www.ncbi.nlm.nih.gov/pubmed/29939785
MLL-Fusion-Driven Leukemia Requires SETD2 to Safeguard Genomic Integrity
Skucha A, Ebner J, Schmöllerl J, Roth M, Eder T, César-Razquin A, Stukalov A, Vittori S, Muhar M, Lu B, Aichinger M, Jude J, Müller AC, Győrffy B, Vakoc CR, Valent P, Bennett KL, Zuber J, Superti-Furga G, Grebien F
Nature communications; May 2018, 9(1): 1983, available at http://www.ncbi.nlm.nih.gov/pubmed/29777171
Pharmacologic Inhibition of STAT5 in Acute Myeloid Leukemia
Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, Tin G, Ahmar S, Lardeau C-H, Sadovnik I, Bajusz D, Keserű GM, Grebien F, Kubicek S, Valent P, Gunning PT, Moriggl R
Leukemia; May 2018, 32(5): 1135–46, available at http://www.ncbi.nlm.nih.gov/pubmed/29472718
STAT5BN642H Is a Driver Mutation for T Cell Neoplasia
Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A, Kolbe T, Elabd M, Halbritter F, Pencik J, Kazemi Z, Grebien F, Hengstschläger M, Kenner L, Kubicek S, Farlik M, Bock C, Valent P, Müller M, Rülicke T, Sexl V, Moriggl R
The Journal of clinical investigation; January 2018, 128(1): 387–401, available at http://www.ncbi.nlm.nih.gov/pubmed/29200404
2017
Nilotinib-Induced Vasculopathy: Identification of Vascular Endothelial Cells as a Primary Target Site
Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P
Leukemia; November 2017, 31(11): 2388–97, available at http://www.ncbi.nlm.nih.gov/pubmed/28757617
Analysis of the Interplay between All-Trans Retinoic Acid and Histone Deacetylase Inhibitors in Leukemic Cells
Noack K, Mahendrarajah N, Hennig D, Schmidt L, Grebien F, Hildebrand D, Christmann M, Kaina B, Sellmer A, Mahboobi S, Kubatzky K, Heinzel T, Krämer OH
Archives of toxicology; May 2017, 91(5): 2191–2208, available at http://www.ncbi.nlm.nih.gov/pubmed/27807597
2016
NVT: A Fast and Simple Tool for the Assessment of RNA-Seq Normalization Strategies
Eder T, Grebien F, Rattei T
Bioinformatics (Oxford, England); December 2016, 32(23): 3682–84, available at http://www.ncbi.nlm.nih.gov/pubmed/27515738
JAK-STAT Signaling in Cancer: From Cytokines to Non-Coding Genome
Pencik J, Pham HTT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F, Kenner L
Cytokine; November 2016, 87: 26–36, available at http://www.ncbi.nlm.nih.gov/pubmed/27349799
Increased Survival and Cell Cycle Progression Pathways Are Required for EWS/FLI1-Induced Malignant Transformation
Javaheri T, Kazemi Z, Pencik J, Pham HT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DN, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R
Cell death & disease; October 2016, 7(10): e2419, available at http://www.ncbi.nlm.nih.gov/pubmed/27735950
2015
Pharmacological Targeting of the Wdr5-MLL Interaction in C/EBPα N-Terminal Leukemia
Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KVM, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G
Nature chemical biology; August 2015, 11(8): 571–78, available at http://www.ncbi.nlm.nih.gov/pubmed/26167872
STAT3 Regulated ARF Expression Suppresses Prostate Cancer Metastasis
Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L
Nature communications; July 2015, 6: 7736, available at http://www.ncbi.nlm.nih.gov/pubmed/26198641
2014
Acceleration of Bcr-Abl+ Leukemia Induced by Deletion of JAK2
Grundschober E, Hoelbl-Kovacic A, Bhagwat N, Kovacic B, Scheicher R, Eckelhart E, Kollmann K, Keller M, Grebien F, Wagner KU, Levine RL, Sexl V
Leukemia; September 2014, 28(9): 1918–22, available at http://www.ncbi.nlm.nih.gov/pubmed/24791858
The Grebien Group 